Biocept receives more than 100,000 COVID-19 samples for processing at its San Diego lab

Biocept Inc (NASDAQ:BIOC) announced Thursday that it has received more than 100,000 samples to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego.

“We are providing COVID-19 testing to a growing list of clients including skilled nursing centers, hospitals, clinics and surgery centers,” CEO Michael Nall said in a statement. 

READ: Biocept wins Hong Kong patent for the enhanced detection of rare cells, including cancer cells

“The majority of our customers are located in California, but we are receiving samples from across the country. We are committed to providing this important service during the pandemic and we continue to return the vast majority of COVID-19 test results to our customers within 48 hours of receiving a sample,” Nall added.

The CEO noted that the testing demand “will have a significant positive impact on our revenues through the remainder of the year and continuing into 2021.”

Last month, the company said its COVID-19 specimen collection kit will now be validated as part of the company’s COVID-19 workflow in its lab prior to being sent to the US Food and Drug Administration for Emergency Use Authorization review. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors